Immune function studies should be conducted as part of the standard nonclinical assessment of safety, even when no signs of immunosuppression have been observed in the standard toxicology studies.  If nonclinical pharmacokinetic studies indicate that the drug and/or metabolites concentrate in immune system tissues (e.g., macrophages), it is useful to determine the potential effect on immune function.